1
Journal of Alzheimer’s Disease xx (20xx) x–xx
DOI 10.3233/JAD-180640
IOS Press
oo
f
Risk of Alzheimer’s Disease in Obstructive
Sleep Apnea Syndrome: Amyloid- and
Tau Imaging
Pr
Alby Eliasa,e,∗ , Tia Cumminsa , Regan Tyrrella , Fiona Lamba , Vincent Doreb , Robert Williamsc ,
Jeffrey Rosenfeldd , Malcolm Hopwoode , Victor L. Villemagnea and Christopher C. Rowea
a Department of Molecular Imaging and Therapy, Austin Health, The University of Melbourne, Victoria, Australia
b CSIRO
Brisbane, Queensland, Australia
Brain Centre, Parkville, Victoria, Australia
d Department of Neurosurgery, Monash University, Victoria, Australia
e Department of Psychiatry, The University of Melbourne, Victoria, Australia
uth
or
c Melbourne
Accepted 31 August 2018
co
rre
cte
dA
Abstract.
Background: An association between obstructive sleep apnea (OSA) and Alzheimer’s disease has been suggested but little
is known about amyloid- and tau deposition in this syndrome.
Objective: To determine amyloid and tau burden and cognitive function in OSA in comparison to those without a diagnosis
of OSA.
Methods: The status of OSA was determined by asking participants about history of polysomnographic diagnosis of OSA and
the use of Continuous Positive Airway Pressure (CPAP). A comprehensive neuropsychological battery measured cognitive
function. Positron emission tomography (PET) was used to measure standardized uptake value ratio (SUVR) of 18 F-florbetaben
and 18 F-AV1451, to quantify amyloid and tau burden.
Results: 119 male Vietnam veterans completed assessment. Impairment in visual attention and processing speed and increased
body mass index (BMI) were seen in subjects with OSA compared with those without a diagnosis OSA. The cortical uptake
of 18 F-florbetaben was higher in the OSA group than in the control group (SUVR: 1.35 ± 0.21 versus 1.27 ± 0.16, p = 0.04).
There were more apolipoprotein E 4 allele (APOE 4) carriers in the OSA group than in the control group. In multilinear
regression analysis, the significance of OSA in predicting 18 F-florbetaben uptake remained independent of age and vascular
risk factors but not when BMI or APOE 4 was adjusted. The reported use of CPAP (n = 14) had no effect on cognitive or
amyloid PET findings. There was no significant difference in 18 F-AV1451 uptake between the two groups.
Conclusions: Obstructive sleep apnea is associated with Alzheimer’s disease pathology, but this relationship is moderated
by APOE 4 and BMI.
INTRODUCTION
Un
Keywords: Alzheimer’s disease, amyloid PET, dementia, obstructive sleep apnea, tau PET
Alzheimer’s disease (AD) is the most common
cause of dementia [1, 2]. The precise mechanism of
∗ Correspondence to: Alby Elias, 343 Burwood Hwy, East Burwood, 3151 Victoria, Australia. Tel.: +61 417325223; Fax: +61 3
98725964; E-mail: alby.elias@unimelb.edu.au.
the disease is still unknown, but investigations over
the past several decades have identified numerous risk
factors for AD [3–9]. Age is the strongest risk factor for AD and genetic factors posit substantial risk
[5, 7, 8]. Neuritic plaques and neurofibrillary tangles
(NFT) are the two cardinal lesions of AD. The plaque
contains a central core of amyloid- (A) and NFT
are intracytoplasmic fibrillar structures composed of
ISSN 1387-2877/18/$35.00 © 2018 – IOS Press and the authors. All rights reserved
A. Elias et al. / Risk of Alzheimer’s Disease in Obstructive Sleep Apnea Syndrome
or
Pr
oo
f
neuropsychological examination, apolipoprotein E
(APOE) 4 status, vascular risk factors, and A
and tau imaging. For the analysis of cognitive functions, subjects with traumatic brain injury (TBI) were
excluded given its impact on cognitive outcomes. All
subjects were screened for a history of polysomnographic diagnosis of OSA and the use of Continuous
Positive Airway Pressure (CPAP) mask. This history
was corroborated by documentation from the primary care doctor of participants whenever possible.
Those with no polysomnographic diagnosis of OSA
or symptoms of OSA were the controls. Considering
the poor sensitivity of the global score of PSQI in
detecting OSA [23], the global score was not used
to diagnose OSA but positive responses to the individual items-cessation of breathing during sleep and
excess daytime sleepiness-were exclusion criteria for
controls.
uth
Assessment of cognitive functions and vascular
risk factors
The neuropsychological examination included
Logical Memory subset test 1 and 2 of Wechsler
Memory Scale (WMS) – Anna Thompson story only
[24], digit span forward and backwards from the
Wechsler Adult Intelligence Scale third edition [25],
categorical fluency test from the Delis-Kaplan Executive Function System [26], Rey Osterrieth Complex
Figure Test (ROCFT) [27] and Trail Making Test
parts A and B [28]. Vascular risk factor score was calculated by giving one point to each of the following:
Diabetes mellitus, hypertension, coronary artery disease, hypercholesterolemia, body mass index (BMI)
above 30, current smoking status, previous history of
stroke, and atrial fibrillation. Sum of all points gave
cumulative vascular risk.
rre
cte
abnormally phosphorylated tau proteins [10, 11].
Given that amyloid plaques and NFT are cardinal
lesions in AD, positron emission tomographic (PET)
imaging using specific radioactive ligands that bind to
amyloid and tau is a useful technique to evaluate the
risk factors of AD. 18 F-florbetaben and 18 F-AV1451
are radio-ligands that have specific affinity for A
and 3R4 R tau aggregates, respectively [12, 13].
Sleep disorders have been investigated as potential
risk factors for AD. Obstructive sleep apnea (OSA)
is a syndrome that is diagnosed in the presence of
clinical symptoms, most commonly excess daytime
sleepiness in conjunction with an apnea-hypopnea
index (AHI) greater than 5 events per hour [14].
The prevalence of OSA in community-based cohorts
has been estimated as 2%–8% and it increases with
age [15, 16]. Early studies demonstrated an association between AD and sleep apnea and a correlation
between the severity of apnea and dementia [17,
18]. Recent investigations have demonstrated a link
between A deposition and sleep disturbances [19].
OSA is associated with earlier onset of both mild cognitive impairment (MCI) and dementia compared to
subjects without OSA [20]. In a small sample of five
patients with MCI, higher AHI and oxygen desaturation index were associated with greater amyloid
deposition [21]. However, little is known about A
and tau imaging in cognitively asymptomatic individuals with OSA. In the present study, we report
cognitive function and A and tau imaging findings
in cognitively asymptomatic patients with OSA.
dA
2
METHODS
Participants recruitment
Un
co
This was a cross-sectional study evaluating AD
risk in community-based Vietnam Veterans. Veterans were recruited via the Older Veterans Psychiatric
Program of the Repatriation Hospital, Austin Health
and advertisement in magazines and newsletters of
Retired Service League and the Vietnam Veterans
Association of Australia. The institutional review
board of Austin Health, a major metropolitan health
service in Melbourne provided ethical approval for
the study. Presence of dementia, existing diagnosis of MCI, psychotic and bipolar affective disorder,
current substance abuse, and any unstable medical condition that could have impacted cognitive
performance or made participation difficult were
exclusions. Assessment consisted of medical history, Pittsburgh Sleep Quality Index (PSQI) [22],
PET imaging
The participants underwent a 20-min PET scan (4
x 5-min frames of emission data collected) acquired
90 min after a slow IV bolus administration of 250
MBq (±10%) of 18 F-florbetaben and 70 min after
the injection of 370 MBq of 18 F-AV1451. Acquisition was performed with a Siemens PET/CT mCT128
and CT attenuation correction was applied. Image
reconstruction used the Ordered Subset Expected
Maximization (OSEM) algorithm. There was no correction for partial volume effect. 18 F-florbetaben and
18 F-AV1451 PET were both analyzed with Computational Analysis of PET from AIBL (CapAIBL)
3
A. Elias et al. / Risk of Alzheimer’s Disease in Obstructive Sleep Apnea Syndrome
p
67.69 ± 5.37
Males = 42
Females = 0
11.43 ± 2.78
34.2% (n = 35)
2.37 ± 1.18
32.56 ± 4.05
68.30 ± 3.86
Males = 77
Females = 0
11.70 ± 2.85
15.9% (n = 69)
1.43 ± 1.16
27.82 ± 4.03
0.47
Statistical analyses
The continuous variables viz., 18 F-florbetaben and
SUVRs and neuropsychological test
scores were analyzed using independent t test while
the categorical variables, OSA and APOE 4 status, were analyzed by Chi-square test. All tests
were two-tailed with 95% confidence interval. Pearson correlation was used to find correlates of both
18 F-florbetaben and 18 F-AV1451 SUVRs and cognitive test scores. Multilinear regression analysis was
then performed with explanatory variables found to
be correlated and associated with 18 F-florbetaben
or 18 F-AV1451 SUVRs and cognitive scores. 18 Fflorbetaben and 18 F-AV1451 SUVRs and cognitive
scores were treated as the dependent variables. General linear model was used to test the interaction
between OSA and amyloid and tau tracer SUVRs
and a visually positive amyloid scan in predicting
cognitive function.
Un
co
18 F-AV1451
oo
Pr
RESULTS
Between March 2014 and June 2017, 170 veterans underwent screening after providing informed
consent. From the consecutive sample, 44 veterans
were excluded: 11 veterans had medical morbidities making participation difficult; seven met criteria
for alcohol abuse; five had existing diagnosis of
MCI; five could not cope with psychiatric assessment
because of post-traumatic stress disorder and perceived stress; one had bipolar affective disorder; one
had claustrophobia; and 14 withdrew from the study
because of inconvenience. After exclusion 126 male
veterans completed neuropsychological assessments
and scans. Seven veterans reported symptoms of OSA
according to PSQI but they did not have polysomnographic evaluation and they were therefore excluded
from the analyses. The data from the remaining
119 veterans were analyzed. A polysomnographically confirmed diagnosis of OSA was present in
42 (35.2%) subjects. The characteristics of participants are shown in Table 1. Twenty-four patients
reported regular use of CPAP; 14 veterans did not
use CPAP; and use was indeterminate in four subjects. The mean duration between the diagnosis of
OSA and the study assessment was 74.35 ± 27.06
months. Veterans with OSA had significantly higher
vascular risk factor score compared with those without OSA (2.37 ± 1.18 versus 1.43 ± 1.16, p < 0.001,
CI = –1.45 to –0.42). BMI was significantly higher
in the OSA group than in the controls (32.56 ± 4.05
versus 27.82 ± 4.03, p < 0.001). There was no significant difference in age or years of education between
the OSA and the control group (Table 1). The characteristics of OSA has been shown in Table 2.
Veterans with OSA and controls did not differ
significantly in the following cognitive functions:
Digit span, categorical fluency, Logical Memory
Test 1 and 2, ROCFT, ROCFT 3-min and 30min delayed recall. However, subjects with OSA
scored significantly higher on Trail Making Test A
rre
cte
software developed by the Commonwealth Scientific
and Industrial Research Organization (CSIRO) [29].
CapAIBL allows quantitative PET measurements
without relying on magnetic resonance imaging [30].
Global A and regional tau burden were calculated
by standardized uptake value ratio (SUVR) using
cerebellar grey matter uptake as the reference. 18 FFlorbetaben scans were also read visually according
to the manufacturer’s instructions by three readers and the classification into negative or positive
scan was based on majority results. 18 F-AV1451
regional uptake in three regions was calculated by
CapAIBL software: Mesial temporal (amygdala, hippocampus, entorhinal cortex, and parahippocampus);
temporoparietal (inferior and middle temporal lobe,
fusiform gyrus, posterior cingulate/precuneus, superior and inferior parietal and lateral occipital cortex);
and rest of the neocortex. A visual read of 18 FAV1451 images was not performed as a standard
method has yet to be developed.
0.62
χ2 = 4.53, p = 0.03
p < 0.001
p < 0.001
or
Education in years
Apolipoprotein E 4
Vascular risk factor score
BMI
Non-OSA group
(n = 77)
uth
Age
Gender
OSA group
(n = 42)
dA
Variables
f
Table 1
Patients characteristics in OSA
4
A. Elias et al. / Risk of Alzheimer’s Disease in Obstructive Sleep Apnea Syndrome
f
oo
(time to completion in seconds: 41.81 ± 12.54 versus 35.63 ± 11.69, p = 0.03, CI = –11.80, to –0.544)
and B (time to completion in seconds: 126.70 ± 82.47
versus 97.95 ± 33.79, p = 0.03, CI = –54.29 to –3.22)
(Table 3). Both test scores positively correlated
with vascular risk factor score (r = 0.24, p = 0.03;
r = 0.22, p = 0.04, respectively). The significant relation between OSA and Trail Making Test B did
not stay when Trail Making Test A, a measure of
visual attention and processing speed was controlled
(R2 = 0.23, p = 0.12). The significance of OSA in predicting Trail Making Tests A (R2 = 0.118, p = 0.04)
remained upon controlling the effects of age, education and APOE 4, but not when vascular risk
factor score was adjusted for (R2 = 0.07, p = 0.16).
In the general linear model analysis, there was
no significant interaction between 18 F-florbetaben
SUVR and OSA or visually positive 18 F-florbetaben
scan and OSA in predicting either Trail Making
Test A or B.
Pr
6 years
24
85.5% (74%–93%)
33.0 (6–89)
or
Mean duration of diagnosis
Regular CPAP users
Mean nadir oxygen saturation
Apnea-hypopnea Index
uth
Variables
The boxplots for the distribution of 18 F-florbetaben
SUVR are given in Fig. 1. Independent t test
showed that the SUVR of 18 F-florbetaben was
significantly higher in the OSA group than in the control group (1.35 ± 0.21 versus 1.27 ± 0.16, p = .04,
CI = –0.14 to –0.003). A greater number of subjects with a visually positive 18 F-florbetaben scan in
the OSA group did not reach significance between
the OSA and control groups (29.7% versus 17.3%,
χ2 = 2.26, p = 0.13). There was no significant increase
in 18 F-AV1451 SUVR in OSA in any regions
studied (Table 3). BMI significantly and positively
correlated with 18 F-florbetaben SUVR (r = 0.341,
p < 0.001) which was significantly higher in those
with obesity (BMI more than 30, n = 48) compared with those who were non-obese (1.37 ± 0.22
versus 1.25 ± 0.13, p < 0.001). Vascular risk score
showed significant positive correlation with global
SUVR of 18 F-florbetaben (r = 0.206, p = 0.049) and
regional SUVRs of 18 F-AV1451 in mesial temporal
(r = 0.327, p = 0.004) and temporoparietal (r = 0.26,
p = 0.03) regions. When separate analysis was done
for the OSA group there was no significant difference between veterans who were regularly using
CPAP and the non-users of CPAP in global 18 Fflorbetaben (1.36 ± 0.23 versus 1.35 ± 0.22, p = 0.82)
or regional 18 F-AV1451 SUVRs. Baseline sleep diagnostic reports were available for 14 subjects. The
dA
Table 2
Characteristics of OSA
rre
cte
Table 3
Cognitive tests scores in OSA
Cognitive tests
Un
co
Digit span
3-min delayed visual recall
30-min delayed visual recall
Categorical fluency
Trial Making Test A test, time to
completion
Trail Making Test B test time to
completion (s)
Recognition
Logical Memory Test 1
Logical Memory test 2
Rey Copy Figure Test
18 F-florbetaben
OSA group
(n = 27)
Non-OSA group
(n = 56)
p
15.78 ± 3.50
17.21 ± 4.98
17.32 ± 4.91
19.44 ± 5.59
41.81 ± 12.54
17.09 ± 4.17
16.28 ± 6.73
16.28 ± 6.73
21.41 ± 4.82
35.63 ± 11.69
0.16
0.53
0.21
0.10
0.03
126.70 ± 82.47
97.95 ± 33.79
0.03
20.03 ± 2.21
11.85 ± 4.65
10.85 ± 4.37
29.74 ± 6.39
20.50 ± 1.67
13.30 ± 4.29
11.37 ± 4.37
29.88 ± 2.66
0.30
0.16
0.61
0.88
Table 4
and 18 F-AV1451 SUVR
Tracer SVURs
OSA
(n = 36)
Non-OSA
(n = 70)
p
(95% CI)
18 F-florbetaben
1.35 ± 0.21
1.24 ± 0.14
1.18 ± 0.10
1.20 ± 0.10
1.27 ± 0.16
1.19 ± 0.12
1.15 ± 0.08
1.17 ± 0.09
0.04
0.09
0.14
0.11
18 F-AV1451
Mesial temporal
18 F-AV1451 Neocortical
18 F-AV1451 Temporoparietal
5
Fig. 1.
18 F-florbetaben
SUVR in OSA and controls.
OSA in predicting 18 F-florbetaben SUVR remained
significant upon controlling for vascular risk score
(R2 = 0.10, p = 0.04) and age (R2 = 0.07, p = 0.03).
Similarly, APOE e4 continued to be a significant predictor of 18 F-florbetaben SUVR when age (R2 = 0.08,
p = 0.02) and vascular risk score (R2 = 0.10, p = 0.04)
were adjusted. OSA did not retain its significance
in predicting a visually positive 18 F-florbetaben
scan (R2 = 0.11, p = 0.12) or 18 F-florbetaben SUVR
(R2 = 0.145, p = 0.971) when APOE 4 or BMI
was added while APOE 4 (p = 0.037) and BMI
remained significant (p = 0.010). In the general linear
model there was no significant interaction (F = 0.11,
p = 0.73) between APOE 4 and OSA in predicting
18 F-florbetaben SUVR (Fig. 2).
Un
co
rre
cte
negative correlation between nadir oxygen saturation
and 18 F-florbetaben SUVR did not reach statistical significance (r = –0.563, p = 0.140). There was
no significant correlation between AHI and 18 Fflorbetaben SUVR (r = –0.316, p = 0.317).
APOE 4 carrier status was available for 104
veterans. There was increased rate of APOE 4
allele in the OSA group compared with the controls (34.2% versus 15.9%, χ2 = 4.53, p = 0.03). The
SUVR for 18 F-florbetaben was significantly higher
in the APOE 4 carriers than in the non-carriers
(1.41 ± 0.21 versus 1.27 ± 0.17, p = 0.02). There
were more visually positive 18 F-florbetaben scans
in APOE 4 carriers than in non-carriers (50% versus 13.2%, χ2 = 14.17, p < 0.001). The SUVR of
18 F-AV1451 did not show a significant difference
between APOE 4 carriers and non-carriers in any
regions. In the multilinear regression analysis with
18 F-florbetaben SUVR as the dependent variable,
vascular risk factor score and APOE 4 were added
to OSA because these variables showed association
and correlation with 18 F-florbetaben SUVR. Age
was also added in view of its well-known correlation with amyloid deposition. The significance of
dA
uth
or
Pr
oo
f
A. Elias et al. / Risk of Alzheimer’s Disease in Obstructive Sleep Apnea Syndrome
DISCUSSION
Cognitive functions
The cognitive functions previously reported to be
impaired in OSA include attention, procedural memory and episodic memory [31–33], processing speed
A. Elias et al. / Risk of Alzheimer’s Disease in Obstructive Sleep Apnea Syndrome
dA
uth
or
Pr
oo
f
6
rre
cte
Fig. 2. Interaction between OSA and APOE 4: In the presence of APOE 4, amyloid burden was more greatly increased in OSA.
Un
co
[34], spatial memory [33], and executive function [35,
36], Executive dysfunction has been reported in Vietnam veterans with OSA [35]. Language ability and
psychomotor functions remain relatively unaffected.
In the present study, subjects with OSA performed
poorly on Trail Making Tests A and B. The Trail Making Test A measures visual attention and processing
speed whereas Trail Making Test B assesses executive function. Felver-Gant et al. reported impaired
performance on Trail Making Test B in OSA [35].
We have replicated this finding in subjects with OSA,
but when we controlled for the score of Trail Making
Test A, the effect of visual attention and processing
speed the significance of Trail Making Test B did
not remain indicating that the deficit was actually in
processing speed rather than executive function. The
association between OSA and impairment in these
cognitive domains was independent of age, APOE
4, and education of the subjects, but not vascular risk burden, which was associated with OSA.
The confounding effect of vascular burden was not
adequately addressed in previous studies. A review
of cognitive deficits in OSA has revealed varying
cognitive deficits across studies [37]. The pattern of
cognitive deficits varied according to the assessment
settings (community cohorts against sleep medicine
clinic), treatment with CPAP and age [38, 39]. A
study that compared cognitive functions between
young and older individuals found more attentional
deficits in the older patients, a pattern supported by
our study [37].
Sleep apnea and Alzheimer’s disease
Apart from cognitive impairment, existing data
suggest an association between OSA and MCI and
dementia. A seminal longitudinal study found a twofold risk for MCI or dementia in patients with OSA
over five-year follow-up [20]. Following early observations of association between OSA and dementia
7
A. Elias et al. / Risk of Alzheimer’s Disease in Obstructive Sleep Apnea Syndrome
uth
or
Pr
oo
f
Low-Density Lipoprotein (VLDL) receptor more
slowly than A-APOE 2 and A-APOE 3 complexes leading to decreased clearance of A with
APOE 4 [44]. In general population and clinical
samples, OSA was found to be associated with the
APOE 4 allele [45–47] but other studies and a metaanalysis did not find such an association [48]. We
found a significantly increased rate of APOE 4 in
OSA in our sample but the significantly increased
A tracer retention in OSA was no longer observed
when the effect of APOE 4 was controlled. APOE 4
had stronger association with A burden than OSA.
The influence of OSA on 18 F-florbetaben SUVR was
higher in the presence of APOE 4, than in its absence
(Fig. 2). We did not find a significant difference in tau
retention between the OSA group and controls but
considering that cortical tau deposition follows A
accumulation and may be more closely associated
with cognitive deficits, or dementia, this is not unexpected as our sample excluded subjects with MCI.
Limitations
dA
While the diagnosis of OSA was made with
polysomnographic studies, subjects without a diagnosis of OSA did not have laboratory sleep evaluation. The corollary is that some of the control subjects
may have undiagnosed OSA. Therefore, the control
group is not really a group without OSA; rather it is
a group without symptoms of OSA. In our study we
used PSQI, a sleep questionnaire that elicits symptoms of arrested breathing during sleep and daytime
sleepiness. One study has reported that PSQI has poor
sensitivity (38%) in screening for OSA, but this study
used global PSQI score, not the responses to individual questions that are most relevant to OSA [23]. We
excluded the participants who reported symptoms of
OSA on PSQI. The rate of OSA in our sample (35.2%)
is higher than the prevalence of OSA reported in the
older general community (17%–24%) suggesting that
Australian Vietnam veterans are well monitored for
this condition and at low risk for missed diagnosis
[49]. Our sample was primarily veterans with military
deployment. This may limit generalizability of the
above findings. The correlational analysis between
nadir oxygen saturation and 18 F-florbetaben SUVR
involved a small sample and type II error needs to
be considered in this context. It is noteworthy that
the subject with highest 18 F-florbetaben SUVR (2.01)
had the lowest oxygen saturation (74%). Therefore,
an association between oxygen desaturation and A
in OSA cannot be ruled out.
Un
co
rre
cte
further findings have accrued recently supporting the
link between sleep disordered breathing and both
MCI and dementia [18–20]. A recent study demonstrated annual decline in the level of cerebrospinal
fluid (CSF) A42 over a two-year period in cognitively asymptomatic elderly patients with OSA,
implying increased risk of AD in this condition [40].
The change in CSF A42 correlated with the severity of OSA independent of APOE. However, there
was no association between OSA and increased amyloid uptake on PET scan. The results of the present
study show that patients with a polysomnographic
diagnosis of OSA have slight but significantly higher
global uptake of 18 F-florbetaben compared to subjects without a diagnosis OSA. This association was
independent of age and vascular risk factors, but not
APOE 4 or BMI. Both BMI and APOE 4 were associated with 18 F-florbetaben SUVR. Previous studies
have suggested a negative correlation between BMI
and amyloid load [41, 42]. The relationship between
dementia and BMI is two-phased, increased risk of
dementia was seen with BMI when weight was measured 20 years or more prior to dementia diagnosis
and this association was reversed when weight was
measured in 10 years or less before dementia diagnosis [43]. The first phase may represent a causal effect
of obesity on dementia and the second phase is due
to weight loss from metabolic changes arising from
damage to medial temporal lobe during long preclinical stage of AD. The mean age of our subjects was
68.36 years suggesting that the participants have not
yet reached the stage of declining weight which may
commence with increasing amyloid accumulation at
any stage later.
There was no significant difference in regional
uptakes of 18 F-AV-1451 between the groups.
Recently a small study found increased amyloid
deposition in elderly patients with MCI and OSA in
correlation with oxygen desaturation index [21]. Such
a correlation was not found in cognitively normal
individuals with OSA [21], but the sample sizes of
this study were very small, eight patients with normal
cognitive function and five patients with MCI. Our
subjects were elderly without an existing diagnosis
of MCI.
Interaction between sleep apnea and APOE 4
The mechanism through which OSA is associated with dementia and A deposits is not precisely
known. A binding to APOE 4 results in AAPOE 4 complex which is internalized by Very
8
A. Elias et al. / Risk of Alzheimer’s Disease in Obstructive Sleep Apnea Syndrome
[13]
ACKNOWLEDGMENTS
The study was supported by U.S. Department of
Defense and Piramal Pharmaceuticals.
Authors’ disclosures available online (https://
www.j-alz.com/manuscript-disclosures/18-0640r1).
[14]
[15]
[16]
REFERENCES
[17]
[4]
[5]
[6]
[7]
[8]
[9]
dA
[18]
[19]
[20]
rre
cte
[3]
co
[2]
Fratiglioni L, Grut M, Forsell Y, Viitanen M, Grafström M,
Holmén K, Ericsson K, Bäckman L, Ahlbom A, Winblad B
(1991) Prevalence of Alzheimer’s disease and other dementias in an elderly urban population: Relationship with age,
sex, and education. Neurology 41, 1886-1892.
Shoenberg BS, Kokmen E, Okazaki H (1987) Alzheimer’s
disease and other dementing illnesses in a defined United
States population: Incidence rates and clinical features. Ann
Neurol 22, 724-772.
Jorm AF (2005) Risk factors for Alzheimer’s disease. In
Dementia, 3rd Edn, Burns A, O’Brien J, Ames D, eds.
Hodder Arnold, Boca Raton.
Launer LJ, Anderson K, Dewey ME, Letenneur L, Ott,
A, Amaducci LA, Brayne C, Copeland JR, Dartigues JF,
Kragh-Sorensen P, Lobo A, Martinez-Lage JM, Stijnen T,
Hofman A (1999) Rates and risk factors for dementia and
Alzheimer’s disease: Results from EURODEM pooled analyses. Neurology 52, 78-84.
Lindsay J, Laurin D, Verreault R, Hebert R, Helliwell B,
Hill GB, McDowell I (2002) Risk factors for Alzheimer’s
disease: A prospective analysis from the Canadian Study of
Health and Aging. Am J Epidemiol 56, 445-453.
Kivipelto M, Ngandu T, Fratiglioni L Viitanen M, Kåreholt
I, Winblad B, Helkala EL, Tuomilehto J, Soininen H, Nissinen A (2005) Obesity and vascular risk factors at midlife and
the risk of dementia and Alzheimer disease. Arch Neurol 62,
1556-1560.
Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA,
Mayeux RH, Pericak-Vance MA, Risch N, van Dujin CM
(1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer
disease. A meta-analysis. APOE and Alzheimer Disease
Meta-Analysis Consortium. JAMA 278, 1349-1356.
Mayeux R, Sano M, Chen J, Tatemichi T, Stern Y (1991)
Risk of dementia in first-degree relatives of patients with
Alzheimer’s disease and related disorders. Arch Neurol 48,
269-73.
Jorm AF, Jolley D (1998) The incidence of dementia: A
meta-analysis. Neurology, 51, 728-733.
Un
[1]
f
[12]
oo
[11]
Pr
We identify an association between obstructive
sleep apnea and increased A deposition. However,
the association with A deposition was moderated by
APOE 4 and BMI. Overall the study does not support a direct association between OSA and increased
A deposition. Likewise, an association between
obstructive sleep apnea and increased tau retention
was not established in this study.
Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein
in Alzheimer disease and Down syndrome. Proc Natl Acad
Sci U S A 82, 4245-4249.
Bancher C, Brunner C, Lassmann H, Budka H, Jellinger K,
Wiche G, Seitelberger F, Grundke-Iqbal I, Wisniewski HM
(1989) Accumulation of abnormally phosphorylated x precedes the formation of neurofibrillary tangles in Alzheimer’s
disease. Brain Res 477, 90-99.
Sabri O, Seibyl J, Rowe C, Barthel H (2015) Beta-amyloid
imaging with florbetaben. Clin Transal Imaging 3, 13-26.
Lowe VJ, Curran G, Fang P, Liesinger AM, Josephs KA,
Parisi JE, Kantarci K, Boeve BF, Pandey MK, Bruinsma
T, Knopman DS, Jones DT, Petrucelli L, Cook CN, GraffRadford NR, Dickson DW, Petersen RC, Jack CR Jr, Murray
ME (2016) An autoradiographic evaluation of AV-1451 Tau
PET in dementia. Acta Neuropathol Commun 4, 58.
Kryger MF, Roth T, Dement WC (editors) (2015) Principles
and practice of sleep medicine. Expert Consult premium
edition. Elsevier Saunders.
Punjabi NM (2008) The epidemiology of adult obstructive
sleep apnea. Proc Am Thorac Soc 5, 136-143.
Peppard PE, Young T, Barnet JH Palta M, Hagen EW, Hla
KM (2013) Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol 177, 1006-1014.
Hoch CC, Reynolds CF, Houck PR Houck PR, Berman SR,
Stack JA (1986) Sleep-disordered breathing in normal and
pathologic aging. J Clin Psychiatry 47, 499-503.
Reynolds CF, Kupfer DJ, Taska LS Hoch CC, Sewitch DE,
Restifo K, Spiker DG, Zimmer B, Marin RS, Nelson J, et
al. (1985) Sleep apnea in Alzheimer’s dementia: Correlation
with mental deterioration. J Clin Psychiatry 46, 257-261.
Mander BA, Marks SM, Vogel JW, Rao V, Lu B, Saletin
JM, Ancoli-Israel S, Jagust, WJ, Walker MP (2015) amyloid disrupts human NREM slow waves and related
hippocampus-dependent memory consolidation. Nat Neurosci 18, 1051-1057.
Osorio RS, Gumb T, Pirraglia T, Varga AW, Lu S, Lim J,
Wohlleber ME, Ducca EL, Koushyk V, Glodzik L, Mosconi
L, Ayappa I, Rapoport DM, de Leon MJ (2015) Sleep disordered breathing advances cognitive decline in the elderly.
Neurology 84, 1964-1971.
Spira AP, Yager C, Brandt J, Smith GS, Zhou Y, Mathur A,
Kumar A, Braăić JR, Wong DF, Wu MN (2014) Objectively
measured sleep and -amyloid burden in older adults: A
pilot study. SAGE Open Med 2, 2050312114546520.
Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ
(1989) The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res
28, 193-213.
Scarlata S, Pedone C, Curcio G, Cortese L, Chiurco D,
Fontana D, Calabrese M, Fusiello R, Abbruzzese G, Santangelo S, Zito A, Incalzi RA (2013) Pre-polysomnographic
assessment using the Pittsburgh Sleep Quality Index questionnaire is not useful in identifying people at higher
risk for obstructive sleep apnea J Med Screen 20,
220-226.
Wechsler D (1987) Wechsler Memory Scale-Revised. The
Psychological Corporation, San Antonio, TX.
Wechsler D (1997) Wechsler Adult Intelligence Scale - Third
Edition. The Psychological Corporation, San Antonio, TX.
Butters, N, Granholm E, Salmon DP, Grant I, Wolfe J
(1987) Episodic and semantic memory: A comparison of
amnesic and demented patients. J Clin Exp Neuropsychol 9,
479-497.
or
[10]
uth
CONCLUSION
[21]
[22]
[23]
[24]
[25]
[26]
9
A. Elias et al. / Risk of Alzheimer’s Disease in Obstructive Sleep Apnea Syndrome
[33]
[34]
[35]
[36]
[37]
[38]
[39]
[44]
oo
f
[43]
Pr
[42]
or
[32]
[41]
uth
[31]
impairment and dementia in older women. JAMA 306,
613-619.
Sharma RA, Varga AW, Bubu AM, Pirraglia E, Kam K,
Parekh A, Wohlleber M, Miller MD, Andrade A, Lewis C,
Tweardy S, Buj M, Yau PL, Sadda R, Mosconi L, Li Y, Butler
T, Glodzik L, Fieremans E, Babb JS, Blennow K, Zetterberg
H, Lu SE, Badia SG, Romero S, Rosenzweig I, Gosselin N,
Jean-Louis G, Rapoport DM, de Leon MJ, Ayappa I, Osorio
RS (2017) Obstructive sleep apnoea severity affects amyloid
burden in cognitively normal elderly: A longitudinal study.
Am J Respir Crit Care Med 197, 933-943.
Vidoni ED, Townley RA, Honea RA, Burns JM (2011)
Alzheimer’s Disease Neuroimaging Initiative. Alzheimer
disease biomarkers are associated with body mass index.
Neurology 77, 1913-1920.
Hsu DC, Mormino EC, Schultz AP, Amariglio RE, Donovan NJ, Rentz DM, Johnson KA, Sperling RA, Marshall
GA Harvard Aging Brain Study (2016) Lower late-life
body-mass index is associated with higher cortical amyloid burden in clinically normal elderly. J Alzheimers Dis
53, 1097-1105.
Kivimaki M, Luukkonen R, Batty GD, Ferrie JE, Pentti
J, Nyberg ST, Shipley MJ, Alfredsson L, Fransson EI,
Goldberg M, Knutsson A, Koskenvuo M, Kuosma E,
Nordin M, Suominen SB, Theorell T, Vuoksimaa E, Westerholm P, Westerlund H, Zins M, Kivipelto M, Vahtera J,
Kaprio J, Singh-Manoux A, Jokela M (2018) Body mass
index and risk of dementia: Analysis of individual-level
data from 1.3 million individuals. Alzheimer Dement 14,
601-609.
Deane R1, Sagare A, Hamm K, Parisi M, Lane S, Finn MB,
Holtzman DM, Zlokovic BV (2008) apoE isoform-specific
disruption of amyloid beta peptide clearance from mouse
brain. J Clin Invest 118, 4002-4013.
Kadotani H, Kadotani T, Young T, Peppard PE, Finn L,
Colrain IM, Murphy GM Jr, Mignot E (2001) Association
between apolipoprotein E epsilon4 and sleep disordered
breathing in adults. JAMA 285, 2888-2890.
Gottlieb DJ, DeStefano AL, Foley DJ, Mignot E, Redline
S, Givelber RJ, Young T (2004) APOE epsilon4 is associated with obstructive sleep apnea/hypopnea: The Sleep
Heart Health Study. Neurology 63, 664-668.
Lemoine P, Sassolas A, Lestra C, Laforest L, Chamba G
(2004) Is there an interaction between sleep-disordered
breathing, depression and apolipoprotein E phenotype?
L’Encephale 30, 360-362.
Thakre TP, Mamtani MR, Kulkarni H (2009) Lack of association of the APOE epsilon 4 allele with the risk of obstructive
sleep apnea: Meta-analysis and meta-regression. Sleep 32,
1507-1511.
Ancoli-Israel S, Kripke DF, Ancoli-Israel S, Klauber MR,
Mason WJ, Fell R, Kaplan O (1991) Sleep-Disordered
Breathing in community-dwelling elderly. Sleep 14,
486-495.
dA
[30]
[40]
[45]
rre
cte
[29]
co
[28]
Rey A, Osterrieth PA (1993) Translations of excerpts
from Rey’s ‘Psychological Examination of Traumatic
Encephalopathy’ and Osterrieth’s ‘The Complex Figure
Test’. Clin Neuropsychol 7, 2-21.
Reitan RM (1958) Validity of the Trail Making Test as an
indicator of organic brain damage. Percept Mot Skills 8,
271-276.
Zhou L, Salvado O, Dore V, Bourgeat P, Raning P, Macaulay
SL, Ames D, Masters CL, Ellis KA, Villemagne VL,
Rowe CC, Fripp J, AIBL Research Group (2014) MR-Less
surface-based amyloid assessment based on 11 C PiB PET.
PLoS 9, e84777.
Bourgeat P, Villemagne VL, Dore V, Brown B, Macaulay
SL, Martins R, Masters CL, Ames D, Ellis K, Rowe CC, Salvado O, Fripp J, AIBL Research Group (2015) Comparison
of MR-Less PiB SUVR quantification methods Neurobiol
Aging 36, S159-166.
Cosentino FII, Bosco P, Drago V, Prestianni G, Lanuzza B,
Iero I, Tripodi M, Spada RS, Toscano G, Caraci F, Ferri R.
(2008) The APOE 4 allele increases the risk of impaired
spatial working memory in obstructive sleep apnea. Sleep
Med 9, 831-839.
Mazza S, Pepin JL, Naëgelé B, Plante J, Deschaux C, Lévy
P (2005) Most obstructive sleep apnoea patients exhibit vigilance and attention deficits on an extended battery of tests.
Eur Respir J 25, 75-80.
Naegele B, Launois SH, Mazza S, Feuerstein C, Pepin JL, Levy P (2006) Which memory processes are affected in
patients with obstructive sleep apnea? Sleep 29, 533-544.
Kilpinen R, Saunamaki T, Jehkonen M (2014) Information
processing speed in obstructive sleep apnea syndrome: A
review. Acta Neurol Scand 129, 209-218.
Felver-Gant JC, Bruce AS, Zimmerman M, Sweet LH,
Milmman RP, Aloia MS (2007) Working memory in
obstructive sleep apnea: Construct validity and treatment
affects. J Clin Sleep Med 6, 589-594.
Andreou G, Vlachos F, Makanikas K (2012) Neurocognitive Deficits in Patients with Obstructive Sleep
Apnea Syndrome (OSAS), Neuroscience, Dr. Thomas
Heinbockel (Ed.), ISBN: 978-95351-0617-3, In Tech, Available from: http://www.intechopen.com/books/neuroscience/
neurocognitive-deficits-inpatients-with-obstructive-sleepapnea-syndrome-osas.
Alchanatis M, Zias N, Deligiorgis N, Liappas I, Chroneou
A, Soldatos C, Roussos C (2008) Comparison of cognitive
performance among different age groups in patients with
obstructive sleep apnea. Sleep Breath 12, 17-24.
Naegele B, Pepin JL, Levy P, Bonnet C, Pellat J, Feuerstein C (1998) Cognitive executive dysfunction in patients
with obstructive sleep apnea syndrome (OSAS) after CPAP
treatment. Sleep 21, 392-397.
Yaffe K, Laffan AM, Harrison SL, Redline S, Spira AP,
Ensrud KE, Ancoli-Israel S, Stone KL (2011) Sleepdisordered breathing, hypoxia, and risk of mild cognitive
Un
[27]
[46]
[47]
[48]
[49]